Ondine Biomedical (LSE:OBI) has released fuller safety and tolerability data from its pivotal Phase 3 LANTERN trial, reporting a treatment-related adverse event rate of 0.31%, all of them mild. The data were presented at IDWeek 2026 in Washington, D.C.

What was announced

AIM-quoted Ondine Biomedical (LSE:OBI) Inc. said on 28 October 2026 that additional safety and patient-reported tolerability results from its Phase 3 LANTERN trial had been presented at IDWeek 2026, as Poster P-1520. The poster was co-presented with the company's partner, HCA Healthcare's institute (HRI).

The new data build on topline results announced in September 2026, which had already reported no treatment-related serious adverse events (SAEs). The latest release confirms that finding and adds detail on the frequency and nature of milder side effects, as well as how patients rated the experience of treatment.

LANTERN, short for Light-Activated Antimicrobial Therapy to Prevent Surgical Site Infections, is a pivotal, cluster-randomised, crossover, controlled superiority study. It enrolled 5,188 patients undergoing major surgery at 18 hospitals in the US and Canada. The trial compares clinician-administered, non-antibiotic nasal photodisinfection plus standard of care against standard of care alone, with the aim of preventing surgical site infections.

The numbers

The safety analysis covered 2,543 participants who received nasal photodisinfection between 27 December 2024 and 27 April 2026. Of these, eight participants experienced a treatment-related adverse event, a rate of 0.31%. The company said all of these events were mild, citing examples such as temporary nasal soreness, mild burning and transient bleeding. There were no treatment-related SAEs.

Patient-reported measures were also disclosed. Of 2,310 respondents, 2,249 (97.4%) rated the treatment "very bearable" or "bearable". On willingness to repeat, 2,203 of 2,309 respondents (95.4%) said they were "very likely" or "likely" to accept the treatment again if it were prescribed. The release does not break down the responses of the remaining participants in either measure.

For context, the company restated its September topline efficacy result: LANTERN met its prespecified Bayesian primary efficacy endpoint, with nasal photodisinfection plus standard of care showing a 40.5% lower risk of 30-day surgical site infection compared with standard of care alone. No new efficacy figures were included in this announcement.

Dr Ken Sands, Chief Epidemiologist at HCA Healthcare and part of the HRI study team, said the treatment was very well tolerated by patients in a real-world clinical setting. Chief executive Carolyn Cross said the very low number and mild nature of treatment-related adverse events "reinforce the practical suitability of nasal photodisinfection for preoperative use."

Background

Ondine is a Canadian life sciences company developing light-activated antimicrobial, or photodisinfection, therapies. The company describes its approach as non-antibiotic, working through a multi-pathway oxidative mechanism that it says carries a low risk of resistance developing. Beyond surgical site infection prevention, its pipeline includes programmes in chronic sinusitis, ventilator-associated pneumonia and burns.

Its lead product, Steriwave®, is authorised for nasal decolonisation in Canada, the UK and certain other international markets. In the US, however, the nasal photodisinfection technology is not approved or cleared by the Food and Drug Administration (FDA), is not commercially available, and is limited to investigational use under federal law. Any future US marketing would require FDA review and approval.

What to watch next

Ondine said the safety and tolerability data "further define the clinical profile" of nasal photodisinfection as it advances its planned US regulatory submission. The announcement does not give a date for that submission, nor any indication of the likely timetable for an FDA decision.

The company added that further detailed analyses of the primary endpoint, together with key secondary and exploratory endpoints, are ongoing and will be reported "in due course". No financial information, commercial guidance or revenue figures were included in the release.